EU: Pivotal Moment For Roche’s Faster-To-Apply Breast Cancer Combo

Patients preferred subcutaneous injection compared to standard intravenous administration

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".